Hide Message

Updating the Resource Centre Digital Platform

The Business & Human Rights Resource Centre is at a critical point in its development. Our digital platform is home to a wealth of information on business and human rights, but hasn’t had a visual refresh for a number of years.

We will soon be updating the site to improve its usability and better serve the thousands of people that use our site to support their work.

Please take an advance peek at our new look, and let us know what you think!

Thank you,
Alex Guy, Digital Officer

Find Out More Hide Message

Interfaith Center on Corporate Responsibility - new report on pharmaceutical firms' responses to AIDS

In August 2006, the Interfaith Center on Corporate Responsibility (ICCR) issued a report, "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets".  A PowerPoint summary of the report, which includes scores and "bottom line" assessment of each company, is available here.  The Business & Human Rights Resource Centre invited the 15 benchmarked companies to respond to the report; the results to date are indicated below.  Below the companies' responses are rejoinders by ICCR and Physicians for Social Justice (Nigeria) to the companies' responses, and a November 2006 follow-up report by ICCR.

COMPANY RESPONSES / NON-RESPONSES:

Abbott Laboratories statement [DOC]

AstraZeneca response [DOC]

Boehringer-Ingelheim response [DOC]

Bristol-Myers Squibb response [DOC]

Eli Lilly - declined to respond

Gilead Sciences - declined to respond

GlaxoSmithKline response [DOC]

Hoffman-La Roche - declined to respond

Merck response [PDF]

Novartis response [DOC]

Pfizer response [PDF]

sanofi-aventis - declined to respond

Schering-Plough - declined to respond

Tibotec (part of Johnson & Johnson) response [DOC]

Wyeth - press release sent in response to ICCR report

REJOINDERS:

ICCR statement regarding the company responses (6 Nov 2006) [DOC]

Physicians for Social Justice (Nigeria) rejoinder to the company responses [DOC]
Novartis response to Physicians for Social Justice [DOC]

NOV 2006 ICCR UPDATE:

Benchmarking AIDS: 2006 Year End Update [PDF]
- includes recent steps taken by Abbott, Gilead, GlaxoSmithKline, Novartis, Roche & recommendations for next steps for each of these companies

Get RSS feed of these results

All components of this story

Company non-response
4 March 2014

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Read the full post here

Article
30 November 2006

[PDF] Benchmarking AIDS: 2006 Year End Update

Author: Interfaith Center on Corporate Responsibility [USA]

Pharmaceutical companies continue to fall short on providing access to essential medicines... However, investors found that some companies have taken steps towards improving public health in poor countries and protecting long-term shareholder value... [Includes recent steps by Abbott, Gilead, GlaxoSmithKline, Novartis, and Roche and recommendations for next steps for each of these companies.]

🚫Read the full post here

Company response
13 September 2006

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Read the full post here

Company response
13 September 2006

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Read the full post here

Company response
13 September 2006

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Read the full post here

Article
12 September 2006

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Author: Compiled by Business & Human Rights Resource Centre

In August 2006, the Interfaith Center on Corporate Responsibility issued a report, "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"...The Business & Human Rights Resource Centre invited the 15 benchmarked companies to respond to the report; the results to date are indicated below. - Abbott Laboratories statement - AstraZeneca response - Boehringer-Ingelheim response - Bristol-Myers Squibb response - Eli Lilly - declined to respond - Gilead Sciences - declined to respond - GlaxoSmithKline response - Hoffman-La Roche - declined to respond - Merck response - Novartis response - Pfizer response - Tibotec (part of Johnson & Johnson) response - sanofi-aventis: We invited sanofi-aventis to respond; no response has been received. - Schering-Plough - declined to respond - Wyeth - press release sent in response to ICCR report

🚫Read the full post here

Company response
6 September 2006

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Read the full post here

Company response
6 September 2006

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Read the full post here

Article
+ Español - Hide

Author: ComunicaRSE

El Interfaith Center on Corporate Responsibility (ICCR) presentó un informe en el que evalúa a 15 farmacéuticas y concluye que todas están fallando en su aporte a los grandes problemas que enfrentan los países en vías de desarrollo, especialmente en HIV/Sida, malaria y tuberculosis. "Son muertes que podrían evitarse, vidas que podrían alargarse y personas que podrían salvarse, si es que elegimos salvarlas", fue una de las declaraciones más fuertes del reporte...En la categoría "accesibilidad" los autores del reporte sugieren que voluntariamente den la licencia de los genéricos a los productores de países en vías de desarrollo...GlaxoSmithKline...obtuvo los mejores puntajes. Le siguieron...Merck, Bristol-Myers Squibb y Gilead Sciences. Otra empresa que se destacó fue...Sanofi-aventis...Por el contrario, las que obtuvieron peores resultados fueron Abbott...y Boehringer...

🚫Read the full post here

Company non-response
23 August 2006

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.